英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
assesment查看　assesment　在百度字典中的解释百度英翻中〔查看〕
assesment查看　assesment　在Google字典中的解释Google英翻中〔查看〕
assesment查看　assesment　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Best New Migraine Medications and Treatments — Migraine Again
    And the hits keep coming: During 2024 to 2025 alone, four new treatments were approved These new therapies — from prescription drugs, devices, and technology-based treatments — are based on cutting-edge science and are specifically targeted for migraine, unlike past treatments that were made for other conditions
  • New Treatments for Migraines: What Actually Works in 2025?
    This article reviews the most effective migraine treatments available in 2025, focusing on their mechanisms of action, clinical evidence, and their role in modern migraine management These innovations represent a major step forward in addressing the unmet needs of millions living with migraine New Oral Medications for Migraine Relief
  • FDA Approves Symbravo (meloxicam and rizatriptan) for the . . .
    Symbravo is an oral prescription medicine used to treat acute migraine headaches with or without aura in adults Symbravo is not used to prevent or decrease the number of migraine headaches you have or for treatment of hemiplegic or basilar migraines Symbravo is not indicated as a treatment for cluster headaches or for use in children
  • A new era in migraine treatment: Promising drugs in development
    Axsome Therapeutics launches new migraine drug Symbravo Another recently approved migraine treatment is Axsome’s Symbravo, which was finally given the green light by the FDA for the acute treatment of migraine with or without aura in January 2025 after the regulatory agency previously rejected it for manufacturing issues in 2022
  • FDA Approves Symbravo for Acute Treatment of Migraine With or . . .
    “The approval of [Symbravo] as a new acute treatment for migraine is an important step forward, offering a new option for people seeking relief ” 1 REFERENCES 1 Axsome Therapeutics announces FDA approval of Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults News release Axsome





中文字典-英文字典  2005-2009